APUS Apimeds Pharmaceuticals US, Inc. stock chart & analysis
Conviction 45HealthcareScan · Tue, Nov 10, 2026Apimeds Pharmaceuticals US, Inc. (APUS) closed at $2.65 (-1.85%) on Nov 10, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 39, RS Rating 4, -95.1% from its 52-week high, -82.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why APUS moved
From the StockSetups movers recaps that covered APUS, newest first. A recap states what was known that day.
- After hours+30.8%
Apimeds Pharmaceuticals jumped after the bell to $6.12, up +30.8% on 2,608,677 after-hours shares, against a 20-day average of 11,575,473 — so volume was actually below typical levels, which is notable.
After-Hours Movers Oct 9, 2026: YMAT, LNKS, APUS → - Close+52.9%
Multiple financial outlets covered the surge. According to Kalkine Media (October 6), the stock "skyrocketed" on the day, and Benzinga and Yahoo Finance had already flagged APUS gaining on October 5.
Top Stock Movers Oct 6, 2026: MOBX, VCIG, APUS → - After hours+20.5%
Multiple sources from October 5 itself — Benzinga, timothysykes.com, and stockstotrade.com — describe APUS whipsawing throughout the regular session on extreme volatility, drawing day traders targeting price swings rather than a single clean catalyst.
After-Hours Movers Oct 5, 2026: OLOX, JAGX, QTEX → - Close+36.3%
Apimeds Pharmaceuticals US, Inc. (APUS) closed up +36.3% to $4.39 on 21,010,688 shares — about 2.8× its 20-day average of 7,536,389. The stock gapped up +53.7% at the open and then whipsawed through the session, closing well below intraday highs.
Top Stock Movers Oct 5, 2026: MI, VEEA, BEAT → - Premarket+67.1%
No hard fundamental catalyst is evident from the available data. The most recent SEC filing is a neutral 8-K from October 1 flagging a management change — the appointment of Eric Sherb as the new CFO.
Premarket Movers Oct 5, 2026: MI, BEAT, ALEC → - Close+47.4%
No specific fundamental catalyst — no earnings release, no FDA decision, no partnership — appears in today's headlines.
Top Stock Movers Sept 25, 2026: MSGY, INLF, AIFF →
Financials as of Tue, Jun 30, 2026 · quarterly.
APUS technical analysis
Trend
APUS is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 23.7% below the 50-day ($3.47) and 71.7% below the 200-day ($9.36). ADX(14) at 12 points to a weak trend — more range than direction. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 39, in the bearish half of its range. The MACD histogram is negative. Its RS Rating of 4 puts its weighted 12-month performance ahead of about 4% of the US market.
Volume and volatility
Volume on the latest session ran 0.0× its 20-day average. It trades about $224,866 a day on average. ATR(14) is $0.5887, 22.2% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (0.25) shows accumulation.
Key levels
The chart pattern's support is $2.00 and its resistance $9.49. The 52-week range is $1.51 to $53.73; price is 95.1% below the high and 75.5% above the low. The VWAP anchored at the 52-week high is $6.35, above price.
Performance
APUS returned -10.8% (1 week), -49.0% (1 month), -43.1% (3 months), -78.0% (6 months), -84.2% (1 year), -82.0% (year to date).
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
Pharmaceutical Preparations · Listed 2025 · 7 employees
SEC filings
EDGAR filings in APUS · 9 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.